Orforglipron for Obesity
(ATTAIN-1 Trial)

Recruiting in Palo Alto (17 mi)

+171 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Eli Lilly and Company

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial will test the safety and effectiveness of an oral medication called orforglipron in adults who are obese or overweight and have related health problems. The medication aims to help reduce body weight by possibly affecting appetite or metabolism.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for adults with obesity or overweight who also have weight-related health issues like high blood pressure, sleep apnea, heart disease, or high cholesterol. Participants should have a BMI of 30 or higher and a history of unsuccessful dieting to lose weight.

Inclusion Criteria

Have a BMI

≥30.0 kilogram/square meter (kg/m²)

Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.

See 1 more

Treatment Details

Interventions

Orforglipron (Other)
Placebo (Other)

Trial OverviewThe study is testing Orforglipron, an oral medication taken once daily, against a placebo to see if it's effective and safe in helping people with obesity or overweight reduce their body weight.

Participant Groups

4Treatment groups

Experimental Treatment

Placebo Group

Group I: Orforglipron Dose 3Experimental Treatment1 Intervention

Participant will receive orforglipron administered orally.

Group II: Orforglipron Dose 2Experimental Treatment1 Intervention

Participant will receive orforglipron administered orally.

Group III: Orforglipron Dose 1Experimental Treatment1 Intervention

Participant will receive orforglipron administered orally.

Group IV: PlaceboPlacebo Group1 Intervention

Participants will be given placebo.